


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents  
Washington, D.C. 20231 on October 3, 2002

  
Doran R. Pace, Patent Attorney

DT06 Rec'd PCT/PTO 07 OCT 2002 *Oct*

INFORMATION DISCLOSURE  
STATEMENT  
Patent Application  
Docket No. FSU-100C2XC1  
Serial No. 10/089,875

*5030*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : John L. Teem  
Serial No. : 10/089,875  
Filed : April 3, 2002  
For : Materials and Methods for Detecting Interaction of CFTR Polypeptides

*#7*

Assistant Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§1.97 AND 1.98


Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicant respectfully asserts that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Doran R. Pace  
Patent Attorney  
Registration No. 38,261  
Phone No.: 352-375-8100  
Fax No.: 352-372-5800  
Address: 2421 N.W. 41st Street, Suite A-1  
Gainesville, FL 32606-6669

DRP/sl

Attachments: Form PTO/SB/08; copies of references cited therein.



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/089,875
				Filing Date	April 3, 2002
				First Named Inventor	John L. Teem
				Art Unit	
				Examiner Name	
Sheet	1	of	4	Attorney Docket Number	FSU-100C2XC1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US- 5,283,173	02-01-94	Fields <i>et al.</i>	All
	U2	US- 5,468,614	11-21-95	Fields <i>et al.</i>	All
	U3	US- 5,543,399	08-06-96	Riordan <i>et al.</i>	All
	U4	US-5,674,898	10-07-97	Cheng <i>et al.</i>	All
	U5	US-5,900,360	05-04-99	Welch <i>et al.</i>	All
	U6	US-6,270,954 B1	08-07-01	Welch <i>et al.</i>	All
	U7	US-			
	U8	US-			
	U9	US-			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)					
	F1	WO	94/25607 A1	11-10-94	University of Iowa Research Foundation	All	
	F2	WO	94/04671 A1	03-03-94	Genzyme Corporation	All	
	F3	WO	97/37645 A1	10-16-97	The Regents of the University of California	All	
	F4	CA	2,037,478	09-06-91	Genzyme Corporation	All	
	F5						
	F6						
	F7						

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/089,875
				Filing Date	April 3, 2002
				First Named Inventor	John L. Teem
				Group Art Unit	
				Examiner Name	
Sheet	2	of	4	Attorney Docket Number	FSU-100C2XC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	ANNEREAU, J. P. <i>et al.</i> "Insight into Cystic Fibrosis by Structural Modelling of CFTR First Nucleotide Binding Fold (NBF1)" <i>C. R. Acad. Sci. Paris, Sciences de la vie/Life Sciences</i> , 1997, pp. 113-121, Vol. 320.	
	R2	ARONHEIM, A. <i>et al.</i> "Isolation of an AP-1 Repressor by a Novel Method for Detecting Protein Interactions" <i>Molecular and Cellular Biology</i> , 1997, pp. 3094-3102, Vol. 17, No. 6.	
	R3	BERLIN, V. "Protein Interactions Mediated by Small Molecule Ligands" <i>Variations on the Two-Hybrid Theme</i> , 1997, pp. 259-272, Oxford University Press, New York.	
	R4	BROWN, C. R. <i>et al.</i> "Chemical Chaperones Correct the Mutant Phenotype of the $\Delta F508$ Cystic Fibrosis Transmembrane Conductance Regulator Protein" <i>Cell Stress &amp; Chaperones</i> , 1996, pp. 117-125, Vol. 1, No. 2.	
	R5	CHENG, S. H. <i>et al.</i> "Defective Intracellular Transport and Processing of CFTR Is the Molecular Basis of Most Cystic Fibrosis" <i>Cell</i> , 1990, pp. 827-834, Vol. 63.	
	R6	DENNING, G. M. <i>et al.</i> "Processing of Mutant Cystic Fibrosis Transmembrane Conductance Regulator is Temperature-Sensitive" <i>Nature</i> , 1992, pp. 761-764, Vol. 358, No. 6389.	
	R7	FLOTTE, T. R. <i>et al.</i> "Adeno-associated Virus Vector Gene Expression Occurs in Nondividing Cells in the Absence of Vector DNA Integration" <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1994, pp. 517-521, Vol. 11.	
	R8	GREGORY, R. J. <i>et al.</i> "Maturation and Function of Cystic Fibrosis Transmembrane Conductance Regulator Variants Bearing Mutations in Putative Nucleotide-Binding Domains 1 and 2" <i>Molecular and Cellular Biology</i> , 1991, pp. 3886-3893, Vol. 11, No. 8.	
	R9	HALLOWS, K. R. <i>et al.</i> "Inhibition of Cystic Fibrosis Transmembrane Conductance Regulator by Novel Interaction with the Metabolic Sensor AMP-Activated Protein Kinase" <i>The Journal of Clinical Investigation</i> , 2000, pp. 1711-1721, Vol. 105, No. 12.	
	R10	JOHNSSON, N. <i>et al.</i> "Split Ubiquitin--A Sensor of Protein Interactions In Vivo" <i>The Yeast Two-Hybrid System</i> , 1997, pp. 316-332, Oxford University Press, New York.	
	R11	KARIMOVA, G. <i>et al.</i> "A Bacterial Two-Hybrid System Based on a Reconstituted Signal Transduction Pathway" <i>Proc. Natl. Acad. Sci.</i> , 1998, pp. 5752-5756, Vol. 95.	
	R12	KEEGAN, L. <i>et al.</i> "Separation of DNA Binding from the Transcription-Activating Function of a Eukaryotic Regulatory Protein" <i>Science</i> , 1986, pp. 699-704, Vol. 231.	
	R13	KEREM, B-S. <i>et al.</i> "Identification of the Cystic Fibrosis Gene: Genetic Analysis" <i>Science</i> , 1989, pp. 1073-1080 Vol. 245.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/089,875		
		Filing Date	April 3, 2002		
		First Named Inventor	John L. Teem		
		Group Art Unit			
		Examiner Name			
Sheet	3	of	4	Attorney Docket Number	FSU-100C2XC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R14	KUNZELMAN, K. <i>et al.</i> "Inhibition of Epithelial Na <sup>+</sup> Currents by Intracellular Domains of the Cystic Fibrosis Transmembrane Conductance Regulator" <i>FEBS Letters</i> , 1997, pp. 341-344, Vol. 18020.	
	R15	MA, J. <i>et al.</i> "Deletion Analysis of GAL4 Defines Two Transcriptional Activating Segments" <i>Cell</i> , 1987, pp. 847-853, Vol. 48.	
	R16	NEVILLE, D. C. A. <i>et al.</i> "Expression and Characterization of the NBD1-R Domain Region of CFTR: Evidence for Subunit-Subunit Interactions" <i>Biochemistry</i> , 1998, pp. 2401-2409, Vol. 37.	
	R17	RIORDAN, J. R. <i>et al.</i> "Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA" <i>Science</i> , 1989, pp. 1066-1072, Vol. 245.	
	R18	ROMMENS, J. M. <i>et al.</i> "Identification of the Cystic Fibrosis Gene: Chromosome Walking and Jumping" <i>Science</i> , 1989, pp. 1059-1065, Vol. 245.	
	R19	SATO, S. <i>et al.</i> "Glycerol Reverses the Misfolding Phenotype of the Most Common Cystic Fibrosis Mutation" <i>The Journal of Biological Chemistry</i> , 1996, pp. 635-638, Vol. 271, No. 2.	
	R20	SHEPPARD, D. N. <i>et al.</i> "Expression of Cystic Fibrosis Transmembrane Conductance Regulator in a Model Epithelium" <i>American Physiological Society</i> , 1994, pp. L405-L413, Vol. 266.	
	R21	SHEPPARD, D. N. <i>et al.</i> "Mutations in CFTR Associated with Mild-Disease-Form Cl <sup>-</sup> Channels with Altered Pore Properties" <i>Nature</i> , 1993, pp. 160-164, Vol. 362.	
	R22	SWICK, ANDREW G. <i>et al.</i> , "Promoter-cDNA-Directed Heterologous Protein Expression in <i>Xenopus laevis</i> oocytes" <i>Proc. Natl. Acad. Sci.</i> , 1992, pp. 1812-1816, Vol. 89.	
	R23	TEEM, J. L. <i>et al.</i> "Identification of Revertants for the Cystic Fibrosis ΔF508 Mutation Using STE6-CFTR Chimeras in Yeast" <i>Cell</i> , 1993, pp. 335-346, Vol. 73.	
	R24	TEEM, J. L. <i>et al.</i> "Mutation of R555 in CFTR-ΔF508 Enhances Function and Partially Corrects Defective Processing" <i>Receptors and Channels</i> , 1996, pp. 63-72, Vol. 4.	
	R25	THOREAU, V. <i>et al.</i> "Molecular Cloning, Expression Analysis, and Chromosomal Localization of Human Syntaxin 8 (STX8)" <i>Biochemical and Biophysical Research Communications</i> , 1999, pp. 577-583, Vol. 257, No. 2.	
	R26	WELSH, M. J. <i>et al.</i> "Cystic Fibrosis Gene Therapy Using an Adenovirus Vector: <i>In Vivo</i> Safety and Efficacy in Nasal Epithelium" <i>Human Gene Therapy</i> , 1994, pp. 209-219, Vol. 5.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/089,875
		Filing Date	April 3, 2002
		First Named Inventor	John L. Teem
		Group Art Unit	
Examiner Name			
Attorney Docket Number	FSU-100C2XC1		
Sheet	4	of	4

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R27	WELSH, M. J. <i>et al.</i> "Cystic Fibrosis: The Genetic Defects Underlying This Lethal Disease Have Now Been Shown to Eliminate or Hobble a Critical Channel through which a Constituent of Salt Enters and Leaves Cells" <i>Scientific American</i> , 1995, pp. 52-59.	
	R28	ZABNER, J. <i>et al.</i> "Adenovirus-Mediated Gene Transfer Transiently Corrects the Chloride Transport Defect in Nasal Epithelia of Patients with Cystic Fibrosis" <i>Cell</i> , 1993, pp. 207-216, Vol. 75.	
	R29	ZABNER, J. <i>et al.</i> "Comparison of DNA-Lipid Complexes and DNA Alone for Gene Transfer to Cystic Fibrosis Airway Epithelia In Vivo" <i>Journal of Clinical Investigation</i> , 1997, pp. 1529-1537, Vol. 100, No. 6.	
	R30		
	R31		
	R32		
	R33		
	R34		
	R35		
	R36		
	R37		
	R38		
	R39		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.